ag What's New in Farm Labor? Immigration and the Agricultural Sector By www.migrationpolicy.org Published On :: Wed, 16 Sep 2015 12:18:47 -0400 An expert discussion on the findings of the National Agricultural Workers Survey (NAWS) related to immigrants, along with an overview of farm labor in 2015 and discussion on how current and possible future immigration policies might impact immigrant workers in the agricultural sector. Full Article
ag Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease--A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V By care.diabetesjournals.org Published On :: 2020-03-20T11:50:34-07:00 OBJECTIVE Dysglycemia, in this survey defined as impaired glucose tolerance (IGT) or type 2 diabetes, is common in patients with coronary artery disease (CAD) and associated with an unfavorable prognosis. This European survey investigated dysglycemia screening and risk factor management of patients with CAD in relation to standards of European guidelines for cardiovascular subjects. RESEARCH DESIGN AND METHODS The European Society of Cardiology’s European Observational Research Programme (ESC EORP) European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) V (2016–2017) included 8,261 CAD patients, aged 18–80 years, from 27 countries. If the glycemic state was unknown, patients underwent an oral glucose tolerance test (OGTT) and measurement of glycated hemoglobin A1c. Lifestyle, risk factors, and pharmacological management were investigated. RESULTS A total of 2,452 patients (29.7%) had known diabetes. OGTT was performed in 4,440 patients with unknown glycemic state, of whom 41.1% were dysglycemic. Without the OGTT, 30% of patients with type 2 diabetes and 70% of those with IGT would not have been detected. The presence of dysglycemia almost doubled from that self-reported to the true proportion after screening. Only approximately one-third of all coronary patients had completely normal glucose metabolism. Of patients with known diabetes, 31% had been advised to attend a diabetes clinic, and only 24% attended. Only 58% of dysglycemic patients were prescribed all cardioprotective drugs, and use of sodium–glucose cotransporter 2 inhibitors (3%) or glucagon-like peptide 1 receptor agonists (1%) was small. CONCLUSIONS Urgent action is required for both screening and management of patients with CAD and dysglycemia, in the expectation of a substantial reduction in risk of further cardiovascular events and in complications of diabetes, as well as longer life expectancy. Full Article
ag Square peg in an octagonal hole By blogs.ams.org Published On :: Tue, 14 Apr 2020 14:48:56 +0000 Interview with Ari Nieh, with commentary from Yvonne Lai Like many of us, I began teaching online this Spring. Unlike many of us, I began doing so at the start of the semester. I am co-teaching a class at Michigan … Continue reading → Full Article testing
ag Taiwan baseball league to allow fans back in ballparks amid pandemic By www.upi.com Published On :: Wed, 06 May 2020 23:05:02 -0400 A limited number of fans will be allowed to enter ballparks for games in Taiwan for the first time this season as stay-at-home orders continue to loosen amid the coronavirus pandemic. Full Article
ag Raiders agree to deal with free agent RB Devontae Booker By www.upi.com Published On :: Thu, 07 May 2020 09:55:57 -0400 The Las Vegas Raiders have agreed to a deal with free agent running back Devontae Booker. Full Article
ag Korea's K-League soccer returns with rules against spitting, talking By www.upi.com Published On :: Fri, 08 May 2020 10:49:47 -0400 K-League soccer resumed with a game behind closed doors Friday in South Korea, with players prohibited from spitting and talking. Full Article
ag Smartphone-Based Glucose Monitors and Applications in the Management of Diabetes: An Overview of 10 Salient "Apps" and a Novel Smartphone-Connected Blood Glucose Monitor By clinical.diabetesjournals.org Published On :: 2012-10-01 Joseph TranOct 1, 2012; 30:173-178Practical Pointers Full Article
ag Empowerment and Self-Management of Diabetes By clinical.diabetesjournals.org Published On :: 2004-07-01 Martha M. FunnellJul 1, 2004; 22:123-127Feature Articles Full Article
ag Medical Nutrition Therapy: A Key to Diabetes Management and Prevention By clinical.diabetesjournals.org Published On :: 2010-12-01 Sara F. MorrisDec 1, 2010; 28:12-18Feature Articles Full Article
ag Hypoglycemia in Type 1 and Type 2 Diabetes: Physiology, Pathophysiology, and Management By clinical.diabetesjournals.org Published On :: 2006-07-01 Vanessa J. BriscoeJul 1, 2006; 24:115-121Feature Articles Full Article
ag Diabetes Management Issues for Patients With Chronic Kidney Disease By clinical.diabetesjournals.org Published On :: 2007-07-01 Kerri L. CavanaughJul 1, 2007; 25:90-97Feature Articles Full Article
ag Management of Diabetic Peripheral Neuropathy By clinical.diabetesjournals.org Published On :: 2005-01-01 Andrew J.M. BoultonJan 1, 2005; 23:9-15Feature Articles Full Article
ag Inpatient Management of Hyperglycemia and Diabetes By clinical.diabetesjournals.org Published On :: 2011-01-01 Vasudev MagajiJan 1, 2011; 29:3-9Feature Articles Full Article
ag Diabetic Neuropathy Is a Substantial Burden in People With Type 1 Diabetes and Is Strongly Associated With Socioeconomic Disadvantage: A Population-Representative Study From Scotland By care.diabetesjournals.org Published On :: 2020-03-20T11:50:34-07:00 OBJECTIVE To assess the contemporaneous prevalence of diabetic peripheral neuropathy (DPN) in people with type 1 diabetes (T1D) in Scotland and study its cross-sectional association with risk factors and other diabetic complications. RESEARCH DESIGN AND METHODS We analyzed data from a large representative sample of adults with T1D (N = 5,558). We assessed the presence of symptomatic neuropathy using the dichotomized (≥4) Michigan Neuropathy Screening Instrument Patient Questionnaire score. Logistic regression models were used to investigate associations between DPN and risk factors, as well as with other complications. RESULTS The burden of DPN is substantial with 13% prevalence overall. Adjusting for attained age, diabetes duration, and sex, the odds of DPN increased mainly with waist-to-hip ratio, lipids, poor glycemic control (odds ratio 1.51 [95% CI 1.21–1.89] for levels of 75 vs. 53 mmol/mol), ever versus never smoking (1.67 [1.37–2.03]), and worse renal function (1.96 [1.03–3.74] for estimated glomerular filtration rate levels <30 vs. ≥90 mL/min/1.73 m2). The odds significantly decreased with higher HDL cholesterol (0.77 [0.66–0.89] per mmol/L). Living in more deprived areas was associated with DPN (2.17 [1.78–2.65]) for more versus less deprived areas adjusted for other risk factors. Finally, individuals with prevalent DPN were much more likely than others to have other diabetes complications. CONCLUSIONS Diabetic neuropathy remains substantial, particularly affecting those in the most socioeconomically deprived groups. Those with clinically manifest neuropathy also have a higher burden of other complications and elevated levels of modifiable risk factors. These data suggest that there is considerable scope to reduce neuropathy rates and narrow the socioeconomic differential by better risk factor control. Full Article
ag Look: Fox rescued from between walls of home, garage By www.upi.com Published On :: Fri, 08 May 2020 15:12:34 -0400 Animal rescuers in Britain said a fox was rescued from the narrow gap between the external walls of a house and its garage. Full Article
ag Despite Flurry of Actions, Trump Administration Faces Constraints in Achieving Its Immigration Agenda By www.migrationpolicy.org Published On :: Wed, 24 Apr 2019 10:39:18 -0400 Though it has achieved success in some areas, the Trump administration’s many efforts to stiffen immigration enforcement in the U.S. interior and at the Southwest border are being consistently stymied by court injunctions, existing laws and settlements, state and local resistance, congressional pushback, and migration pressures that are beyond the government’s ability to swiftly address, as this article explores. Full Article
ag New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2) By care.diabetesjournals.org Published On :: 2014-12-01 Hannele Yki-JärvinenDec 1, 2014; 37:3235-3243Emerging Technologies and Therapeutics Full Article
ag Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON By care.diabetesjournals.org Published On :: 2016-05-01 Muh Geot WongMay 1, 2016; 39:694-700Cardiovascular Disease and Diabetes Full Article
ag The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading By care.diabetesjournals.org Published On :: 2017-08-01 Roy W. BeckAug 1, 2017; 40:994-999Perspectives in Care Full Article
ag The Pros and Cons of Diagnosing Diabetes With A1C By care.diabetesjournals.org Published On :: 2011-05-01 Enzo BonoraMay 1, 2011; 34:S184-S190Diabetes Full Article
ag National Standards for Diabetes Self-Management Education and Support By care.diabetesjournals.org Published On :: 2014-01-01 Linda HaasJan 1, 2014; 37:S144-S153National Standards Full Article
ag Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes By care.diabetesjournals.org Published On :: 2013-10-01 Ralph A. DeFronzoOct 1, 2013; 36:3169-3176Emerging Technologies and Therapeutics Full Article
ag Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study By care.diabetesjournals.org Published On :: 2015-03-01 Robert R. HenryMar 1, 2015; 38:412-419Evolving Tactics With Inhibition of Sodium-Glucose Cotransporters Full Article
ag Pathways to Quality Inpatient Management of Hyperglycemia and Diabetes: A Call to Action By care.diabetesjournals.org Published On :: 2013-07-01 Boris DrazninJul 1, 2013; 36:1807-1814Perspectives in Care Full Article
ag Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial By care.diabetesjournals.org Published On :: 2014-06-01 Hans-Ulrich HäringJun 1, 2014; 37:1650-1659Emerging Technologies and Therapeutics Full Article
ag Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes By care.diabetesjournals.org Published On :: 2014-10-01 Michaela DiamantOct 1, 2014; 37:2763-2773Emerging Technologies and Therapeutics Full Article
ag Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum By care.diabetesjournals.org Published On :: 2013-06-01 Itamar RazJun 1, 2013; 36:1779-1788Diabetes Care Expert Forum Full Article
ag Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes By care.diabetesjournals.org Published On :: 2015-12-01 Robert R. HenryDec 1, 2015; 38:2258-2265Special Article Collection: Insulin Full Article
ag Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes By care.diabetesjournals.org Published On :: 2007-06-01 Tina VilsbøllJun 1, 2007; 30:1608-1610BR Emerging Treatments and Technologies Full Article
ag Insulinotropic Action of Glucagonlike Peptide-I-(7-37) in Diabetic and Nondiabetic Subjects By care.diabetesjournals.org Published On :: 1992-02-01 David M NathanFeb 1, 1992; 15:270-276Short Report Full Article
ag Diabetes Prevention in the Real World: Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes and of the Impact of Adherence to Guideline Recommendations: A Systematic Review and Meta-analysis By care.diabetesjournals.org Published On :: 2014-04-01 Alison J. DunkleyApr 1, 2014; 37:922-933Current Concepts of Type 2 Diabetes Prevention Full Article
ag Undiagnosed NIDDM: Clinical and Public Health Issues By care.diabetesjournals.org Published On :: 1993-04-01 Maureen I HarrisApr 1, 1993; 16:642-652Kelly West Lecture 1992 Full Article
ag Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association By care.diabetesjournals.org Published On :: 2015-10-01 Richard A. InselOct 1, 2015; 38:1964-1974Scientific Statement Full Article
ag Consensus Development Conference on the Diagnosis of Coronary Heart Disease in People With Diabetes: 10-11 February 1998, Miami, Florida By care.diabetesjournals.org Published On :: 1998-09-01 American Diabetes AssociationSep 1, 1998; 21:1551-1559Consensus Development Conference Report Full Article
ag Memo: Prior COVID-19 diagnosis 'permanently disqualifying' for U.S. military service By www.upi.com Published On :: Thu, 07 May 2020 13:41:36 -0400 Military Entrance Processing Stations won't process individuals who have had COVID-19 for military service, even if they've fully recovered from the virus, the Pentagon confirmed this week. Full Article
ag Diabetes and Aging: Unique Considerations and Goals of Care By care.diabetesjournals.org Published On :: 2017-04-01 Rita R. KalyaniApr 1, 2017; 40:440-443Emerging Science and Concepts for Management of Diabetes and Aging Full Article
ag Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association By care.diabetesjournals.org Published On :: 2015-10-01 Richard A. InselOct 1, 2015; 38:1964-1974Scientific Statement Full Article
ag PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes By care.diabetesjournals.org Published On :: 2019-09-01 Vanita R. ArodaSep 1, 2019; 42:1724-1732Emerging Therapies: Drugs and Regimens Full Article
ag Impact of Fat, Protein, and Glycemic Index on Postprandial Glucose Control in Type 1 Diabetes: Implications for Intensive Diabetes Management in the Continuous Glucose Monitoring Era By care.diabetesjournals.org Published On :: 2015-06-01 Kirstine J. BellJun 1, 2015; 38:1008-1015Type 1 Diabetes at a Crossroads Full Article
ag Current Challenges and Opportunities in the Prevention and Management of Diabetic Foot Ulcers By care.diabetesjournals.org Published On :: 2018-04-01 William J. JeffcoateApr 1, 2018; 41:645-652Perspectives in Care Full Article
ag The Pros and Cons of Diagnosing Diabetes With A1C By care.diabetesjournals.org Published On :: 2011-05-01 Enzo BonoraMay 1, 2011; 34:S184-S190Diabetes Full Article
ag Management of Inpatient Hyperglycemia and Diabetes in Older Adults By care.diabetesjournals.org Published On :: 2017-04-01 Guillermo E. UmpierrezApr 1, 2017; 40:509-517Emerging Science and Concepts for Management of Diabetes and Aging Full Article
ag Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring By care.diabetesjournals.org Published On :: 2018-11-01 Richard M. BergenstalNov 1, 2018; 41:2275-2280Perspectives in Care Full Article
ag Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability By care.diabetesjournals.org Published On :: 2011-05-01 Alan J. GarberMay 1, 2011; 34:S279-S284Diabetes Treatments Full Article
ag Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial By care.diabetesjournals.org Published On :: 2020-05-01 W. Timothy GarveyMay 1, 2020; 43:1085-1093Emerging Therapies: Drugs and Regimens Full Article
ag Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial By care.diabetesjournals.org Published On :: 2019-12-01 Helena W. RodbardDec 1, 2019; 42:2272-2281Emerging Therapies: Drugs and Regimens Full Article
ag Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes By care.diabetesjournals.org Published On :: 2013-08-01 Itamar RazAug 1, 2013; 36:S139-S144Diabetes Pathophysiology Full Article
ag 2017 National Standards for Diabetes Self-Management Education and Support By care.diabetesjournals.org Published On :: 2017-10-01 Joni BeckOct 1, 2017; 40:1409-1419National Standards Full Article
ag 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) By care.diabetesjournals.org Published On :: 2020-02-01 John B. BuseFeb 1, 2020; 43:487-493Consensus Report Update Full Article
ag Vasodilatory Actions of Glucagon-Like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans With Vascular Insulin Resistance By care.diabetesjournals.org Published On :: 2020-02-20T11:55:30-08:00 OBJECTIVE Obesity is associated with microvascular insulin resistance, which is characterized by impaired insulin-mediated microvascular recruitment. Glucagon-like peptide 1 (GLP-1) recruits skeletal and cardiac muscle microvasculature, and this action is preserved in insulin-resistant rodents. We aimed to examine whether GLP-1 recruits microvasculature and improves the action of insulin in obese humans. RESEARCH DESIGN AND METHODS Fifteen obese adults received intravenous infusion of either saline or GLP-1 (1.2 pmol/kg/min) for 150 min with or without a euglycemic insulin clamp (1 mU/kg/min) superimposed over the last 120 min. Skeletal and cardiac muscle microvascular blood volume (MBV), flow velocity and blood flow, brachial artery diameter and blood flow, and pulse wave velocity (PWV) were determined. RESULTS Insulin failed to change MBV or flow in either skeletal or cardiac muscle, confirming the presence of microvascular insulin resistance. GLP-1 infusion alone increased MBV by ~30% and ~40% in skeletal and cardiac muscle, respectively, with no change in flow velocity, leading to a significant increase in microvascular blood flow in both skeletal and cardiac muscle. Superimposition of insulin to GLP-1 infusion did not further increase MBV or flow in either skeletal or cardiac muscle but raised the steady-state glucose infusion rate by ~20%. Insulin, GLP-1, and GLP-1 + insulin infusion did not alter brachial artery diameter and blood flow or PWV. The vasodilatory actions of GLP-1 are preserved in both skeletal and cardiac muscle microvasculature, which may contribute to improving metabolic insulin responses and cardiovascular outcomes. CONCLUSIONS In obese humans with microvascular insulin resistance, GLP-1’s vasodilatory actions are preserved in both skeletal and cardiac muscle microvasculature, which may contribute to improving metabolic insulin responses and cardiovascular outcomes. Full Article
